Free Content

Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong

Authors: Tam, C. M.1; Chan, S. L.1; Lam, C. W.2; Dickinson, J. M.3; Mitchison, D. A.3

Source: The International Journal of Tuberculosis and Lung Disease, Volume 1, Number 5, October 1997 , pp. 411-416(6)

Publisher: International Union Against Tuberculosis and Lung Disease

Buy & download fulltext article:

Free content The full text is free.

View now:
PDF 2,629kb 


SETTING: A clinical trial of rifapentine in Hong Kong.

OBJECTIVE: Assessment of the bioavailability of the Chinese rifapentine used in the trial.

DESIGN: The contents of rifapentine in serum samples taken from 287 patients during the administration of four batches of the drug was measured by microbiological assay.

RESULTS: An initial comparison of areas under curve obtained in a random allocation to 40 patients of rifapentine either of Western or Chinese origin indicated that the bioavailability of the Chinese drug was 74% of the Western drug. The bioavailability of the second batch was found to be about 66% of the Western drug. The dose of the last two batches of rifapentine was therefore increased from the planned 600 mg to 750 mg, or briefly to 900 mg; serum concentrations were then similar to those obtained with the Western drug. Bioavailability did not change during the use of each drug batch.

CONCLUSION: A comparison of the results obtained in the trial with the initial two batches and the final batches will estimate the effects of rifapentine dose size on its efficacy and toxicity.

Keywords: Hong Kong; bioavailability; dosage; rifapentine

Document Type: Regular Paper

Affiliations: 1: Hong Kong Department of Health, Chest Services Central Office, Wanchai Polyclinic, Hong Kong 2: Ruttonjee Hospital, Wanchai, Hong, Kong 3: Department of Medical Microbiology, St George's Hospital Medical School, London, UK

Publication date: October 1, 1997

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • ingentaconnect is not responsible for the content or availability of external websites
Related content



Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page